Changes in the management of acute myocardial infarction in Southern Tasmania

Journal of Clinical Pharmacy and Therapeutics

Volumn 25, Issue 2, 2000, Pages 111-118

  McNamara, K S ^a   Peterson, G M ^a   Friesen, W T ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOLYTIC AGENT; GEMFIBROZIL; HYPOCHOLESTEROLEMIC AGENT; METOPROLOL; NITRATE; PERINDOPRIL; PRAVASTATIN; SIMVASTATIN; STREPTOKINASE; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL PRACTICE; DEMOGRAPHY; DRUG USE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MORTALITY; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; SIDE EFFECT; TEACHING HOSPITAL; THORAX PAIN;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; DRUG THERAPY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; TASMANIA;

EID: 0034086034     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2000.00269.x     Document Type: Article

References (39)

1. 1. Anon. (1998) ABS Catalogue No. 3303.0 - Causes of Death, Australia. Commonwealth of Australia, 1999. Australian Bureau of Statistics, Canberra.
2. 2. Bizjak ED, Mauro VF. (1998) Thrombolytic therapy: a review of its use in acute myocardial infarction. Annals of Pharmacotherapy, 32, 769-784.
3. 3. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. (1996) Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. New England Journal of Medicine, 335, 1660-1667.
4. 4. Ryan TJ, Antman EM, Brooks NH, et al. (1999) 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation, 100, 1016-1030.
5. 5. Aylward P. (1996) Acute myocardial infarction: early treatment. Australian Prescriber, 19, 52-54.
6. 6. Kizer JR, Cannon CP, McCabe CH, et al. (1999) Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. American Heart Journal, 137, 79-92.
7. 7. Gersh BJ. (1999) Optimal management of acute myocardial infarction at the dawn of the next millennium. American Heart Journal, 138, 188-202.
8. 8. Brand DA, Newcomer LN, Freiburger A, Tian H. (1995) Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. Journal of the American College of Cardiology, 26, 1432-1436.
9. 9. Freemantle N, Cleland J, Young P, Mason J, Harrison J. (1999) β Blockade after myocardial infarction: systematic review and meta regression analysis. British Medical Journal, 318, 1730-1737.
10. 10. Bradford WD, Chen J, Krumholz HM. (1999) Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications. Pharmacoeconomics, 15, 257-268.
11. 11. Dracup K, McKinley SM, Moser DK. (1997) Australian patients' delay in response to heart attack symptoms. Medical Journal of Australia, 116, 233-236.
12. 12. Goldberg RJ, Gurwitz JH, Gore MD. (1999) Duration of, and temporal trends (1994-97) in, prehospital delay in patients with acute myocardial infarction. The Second National Registry of Myocardial Infarction. Archives of Internal Medicine, 159, 2141-2147.
13. 13. Danchin N, Vaur L, Genes N, et al. (1997) Management of acute myocardial infarction in intensive care units in 1995: a nation-wide French survey of practice and early hospital results. Journal of the American College of Cardiology, 30, 1598-1605.
14. 14. Barakat K, Wilkinson P, Deaner A, Fluck D, Ranjadayalan K, Timmis A. (1999) How should age affect management of acute myocardial infarction? A prospective cohort study. Lancet, 353, 955-959.
15. 15. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. (1999) Do 'America's Best Hospitals' perform better for acute myocardial infarction? New England Journal of Medicine, 340, 286-292.
16. 16. Cooper GM, Bell AJ, Peterson GM, Friesen WT. (1994) Treatment of acute myocardial infarction at the Royal Hobart Hospital [Abstract]. Australian Journal of Hospital Pharmacy, 24, 101.
17. 17. European Secondary Prevention Study Group. (1996) Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet, 347, 1203-1207.
18. 18. Barron HV, Bowlby LJ, Breen T, et al. (1998) Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation, 97, 1150-1156.
19. 19. Gottlieb SS, McCarter RJ, Vogel RA. (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. New England Journal of Medicine, 339, 489-497.
20. 20. Leitch JW, McElduff P, Dobson A, Heller R. (1998) Outcome with calcium channel antagonists after myocardial infarction: a community-based study. Journal of the American College of Cardiology, 31, 111-117.
21. 21. Abernethy DR, Schwartz JB. (1999) Calcium-antagonist drugs. New England Journal of Medicine, 341, 1447-1457.
22. 22. Martinez M, Agusti A, Arnau JM, Vidal X, Laporte JR. (1998) Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period. European Journal of Clinical Pharmacology, 54, 203-208.
23. 23. Rich MW. (1998) Therapy for acute myocardial infarction in older persons. Journal of the American Geriatrics Society, 46, 1302-1307.
24. 24. Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ. (1996) Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Annals of Internal Medicine, 124, 283-289.
25. 25. McLaughlin TJ, Soumerai SB, Willison DJ, et al. (1996) Adherence to national guidelines for drug treatment of suspected acute myocardial infarction -evidence for undertreatment in women and the elderly. Archives of Internal Medicine, 156, 799-805.
26. 26. Venturini F, Romero M, Tognoni G. (1999) Patterns of practice for acute myocardial infarction in a population from ten countries. European Journal of Clinical Pharmacology, 54, 877-886.
27. 27. Krumholz HM, Radford MJ, Wang Y, Chen J, Marciniak TA. (1999) Early beta-blocker therapy for acute myocardial infarction in elderly patients. Annals of Internal Medicine, 131, 648-654.
28. 28. Woods KL, Ketley D, Lowy A, et al. (1998) Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Towards an understanding of factors influencing clinical practice. The European Secondary Prevention Study Group. European Heart Journal, 19, 74-79.
29. 29. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. (1999) Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Archives of Internal Medicine, 159, 561-567.
30. 30. Gollub SB. (1999) Is intensive drug therapy appropriate for older patients? [Editorial]. Lancet, 353, 940-941.
31. 31. Mahon NG, Codd MB, O'Rorke C, Egan B, McCann HA, Sugrue DD. (1999) Management and outcome of acute myocardial infarction in older patients in the thrombolytic era. Journal of the American Geriatrics Society, 47, 291-294.
32. 32. Barron HV, Michaels AD, Maynard C, Every NR. (1998) Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Journal of the American College of Cardiology, 32, 360-367.
33. 33. Lim LL, O'Connell RL, Heller RF. (1999) Differences in management of heart attack patients between metropolitan and regional hospitals in the Hunter Region of Australia. Australian and New Zealand Journal of Public Health, 23, 61-66.
34. 34. Ergin A, Abaci A, Sakalli A, et al. (1999) Pharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals. International Journal of Cardiology, 68, 309-316.
35. 35. Chandra NC, Ziegelstein RC, Rogers WJ, et al. (1998) Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction - I. Archives of Internal Medicine, 158, 981-988.
36. 36. O'Connor GT, Quinton HB, Traven ND, et al. (1999) Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. Journal of the American Medical Association, 281, 627-633.
37. 37. Sarasin FP, Maschiangelo ML, Schaller MD, Heliot C, Mischler S, Gaspoz JM. (1999) Successful implementation of guidelines for encouraging the use of beta blockers in patients after acute myocardial infarction. American Journal of Medicine, 106, 499-505.
38. 38. Cano SB, Lemoine K. (1999) Promoting optimal use of β-blockers after myocardial infarction. American Journal of Health-System Pharmacy, 56, 858-859.
39. 39. Badano L, Cassin M, Solinas L, Burelli C, Macor F, Zanuttini D. (1999) Clinical impact of local implementation of agreed guidelines for the management of patients with acute myocardial infarction. Giornale Italiano di Cardiologia, 29, 39-47.